Since the 1980s, gas chromatography has served as a stability-indicating technique for pharmaceutical products, and gas chromatography mass spectrometry (GC-MS) extended that role to trace-level identification of volatile and semi-volatile impurities that concern regulators most today, from residual solvents to genotoxic nitrosamines driving global recalls during the last decade. Well established for separating low molecular weight, thermally stable analytes, GC-MS remains a core platform across drug development, from forced degradation studies through routine release testing.
GC-MS in pharmaceutical analysis: working principle and instrumentation
The gas chromatography mass spectrometry principle rests on two linked separation steps. The gas chromatograph vaporizes and separates volatile, thermally stable analytes on a heated capillary column, carried by an inert gas such as helium or nitrogen, typically using non-polar dimethyl polysiloxane or polar polyethylene glycol stationary phases. Eluting compounds pass through a transfer line into the mass spectrometer, where energetic electrons ionize and fragment each molecule into cation radicals matched against a reference spectral library for identification. Modern GC-MS instrumentation integrates an autosampler, the gas chromatograph, a high-temperature interface, a quadrupole mass analyzer, and a detector under computer control, differing from liquid chromatography (LC-MS) mainly in using electron or chemical ionization rather than electrospray ionization.
Among the advantages of gas chromatography mass spectrometry are a comprehensive, reproducible spectral library and high sensitivity for low-concentration analytes. The trade-off: only volatile, thermally stable, salt-free compounds below roughly 1000 Da are suitable, and many others require derivatization that adds preparation time and limits throughput.
Main applications of GC-MS in drug development: residual solvents, genotoxic impurities, and beyond
GC-MS pharmaceutical applications span the detection of several impurities that have to be controlled before a drug substance or product can be released:
- Residual solvents testing under ICH Q3C requirements: volatile organic compounds in pharmaceuticals are classified into three toxicological categories and commonly analyzed by headspace GC (HS-GC) to minimize excipient interference.
- Genotoxic impurities detection, particularly nitrosamines, which have driven regulatory action since 2018, following the FDA’s market recall of valsartan medicines after the detection of N-nitrosodimethylamine (NDMA). Trace-level GC-MS methods combining electron ionization with microextraction can reach part-per-billion detection limits in active pharmaceutical ingredients, consistent with ICH M7 genotoxic impurities expectations that classify these substances as a “cohort of concern”.
- Forced degradation and impurity profiling, where GC-MS serves as a stability-indicating technique to resolve degradation products and confirm isomerization pathways through matched fragmentation patterns, supporting shelf-life and specification decisions.
- Drug discovery and biomarker profiling, where multidimensional GC extends classical GC-MS to disentangle complex biological matrices and monitor therapeutic response.
Across these, gas chromatography mass spectrometry impurity profiling connects drug development work to manufacturing process understanding and control strategy.
GC-MS method validation: FDA and EMA regulatory requirements
GC-MS method validation for regulatory submission draws on more than a single ICH guideline. For nitrosamines specifically, the US Foods and Drugs Administration (FDA) and the European Medicines Agency (EMA) have required every marketing authorization holder to assess manufacturing-related formation risk since 2019 and perform confirmatory testing where indicated, while the ICH M7 guideline governs how the resulting mutagenic impurities must be classified and controlled, and the European Pharmacopoeia’s 2020 general chapter sets a recommended limit of 0.03 ppm, shaping the sensitivity a method must demonstrate.
More broadly, ICH Q3B sets the reporting, identification, and qualification thresholds impurities must meet in new drug products, while ICH Q2(R2) governs how procedures used to test against those thresholds must be validated: specificity, linearity with a coefficient of determination above 0.995, accuracy and precision within acceptable limits, and robustness confirmed by varying chromatographic conditions.
This type of analytical method validation package is what FDA and EMA reviewers expect behind any GC-MS method development pharmaceutical program intended for filing.
GC-MS vs LC-MS/MS: choosing the right analytical platform for pharmaceutical analysis
The GC-MS vs. LC-MS decision is rarely absolute, since the two techniques address largely non-overlapping analyte spaces:
- GC-MS analysis favors volatile, thermally stable, low molecular weight compounds, including residual solvents and small nitrosamines.
- LC-MS/MS extends coverage to non-volatile, thermolabile, or polar molecules via electrospray ionization, while GC’s derivatization burden has pushed many metabolomics workflows toward LC despite GC’s earlier historical role.
- Platform superiority is analyte-dependent, not absolute: GC-MS/MS has reached quantitation limits up to 50-fold lower than single-quadrupole GC-MS for the same analyte class, and cross-validated comparisons against LC-MS/MS show close agreement for some compounds (within about 16% for the endocannabinoid anandamide) but order-of-magnitude discrepancies for others, such as certain eicosanoids.
In practice, mass spectrometry applications in drug development increasingly rely on both mass spectrometry gas chromatography, and liquid-phase platforms side by side, each covering space the other cannot.
Outsourcing GC-MS analysis to an analytical CRO: capabilities and regulatory readiness
Building a GC-MS method development for a pharmaceutical programs that can withstand FDA or EMA scrutiny requires instrumentation, method know-how, and validation experience not every sponsor keeps in-house, especially at trace levels demanded by genotoxic impurity limits. An experienced analytical CRO partner brings phase-appropriate method development, ICH-aligned validation, and the flexibility to move between GC-MS analysis, LC-MS/MS, and complementary techniques as the impurity profile demands.
At AMSbiopharma, our mass spectrometry services support residual solvent testing, genotoxic impurity screening, and volatile impurity characterization across the CMC development lifecycle, combining GC-MS and LC-MS/MS platforms with deep regulatory expertise.
Contact us to discuss how our analytical capabilities can strengthen your impurity control strategy.
References
Chew YL, Khor MA, Lim YY. Choices of chromatographic methods as stability indicating assays for pharmaceutical products: A review. Heliyon. 2021 Mar 27;7(3):e06553. doi: 10.1016/j.heliyon.2021.e06553
European Medicines Agency. ICH M7 (R2) Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk – Scientific guideline [Internet]. Amsterdam: EMA [cited 2026 Jul 10]. Available from: https://www.ema.europa.eu/en/ich-m7-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-scientific-guideline
European Medicines Agency. ICH Q3C (R9) Residual solvents – Scientific guideline [Internet]. Amsterdam: EMA [cited 2026 Jul 10]. Available from: https://www.ema.europa.eu/en/ich-q3c-r9-residual-solvents-scientific-guideline
Liao GQ, Tang HM, Yu YD, Fu LZ, Li SJ, Zhu MX. Mass spectrometry-based metabolomic as a powerful tool to unravel the component and mechanism in TCM. Chin Med. 2025 May 12;20(1):62. doi: 10.1186/s13020-025-01112-2
Tsikas D. Perspectives of Quantitative GC-MS, LC-MS, and ICP-MS in the Clinical Medicine Science-The Role of Analytical Chemistry. J Clin Med. 2024 Nov 29;13(23):7276. doi: 10.3390/jcm13237276
Witkowska AB, Giebułtowicz J, Dąbrowska M, Stolarczyk EU. Development of a Sensitive Screening Method for Simultaneous Determination of Nine Genotoxic Nitrosamines in Active Pharmaceutical Ingredients by GC-MS. Int J Mol Sci. 2022 Oct 12;23(20):12125. doi: 10.3390/ijms232012125
Zaid A, Hassan NH, Marriott PJ, Wong YF. Comprehensive Two-Dimensional Gas Chromatography as a Bioanalytical Platform for Drug Discovery and Analysis. Pharmaceutics. 2023 Mar 31;15(4):1121. doi: 10.3390/pharmaceutics15041121
